EXPOSURE-RESPONSE RELATIONSHIPS IN TELAPREVIR COMBINATION THERAPY IN TREATMENT-NAIVE GENOTYPE 1 CHRONIC HCV PATIENTS

被引：2
|
作者：
Gordon, S. C. [1 ]
Muir, A. J. [2 ]
Garg, V. [3 ]
Henshaw, J. [3 ]
机构：
[1] Henry Ford Hlth Syst, Detroit, MI USA
[2] Duke Clin Res Inst, Durham, NC USA
[3] Vertex Pharmaceut Inc, Cambridge, MA USA
来源：
JOURNAL OF HEPATOLOGY | 2012年 / 56卷
关键词：
D O I：
10.1016/S0168-8278(12)61128-3
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1116
引用
收藏
页码：S440 / S440
页数：1
相关论文
共 50 条
  • [11] Treatment of chronic HCV genotype 1 infection with telaprevir: a Bayesian mixed treatment comparison of fixed-length and response-guided treatment regimens in treatment-naive and -experienced patients
    Goralczyk, Armin D.
    Cameron, Silke
    Amanzada, Ahmad
    BMC GASTROENTEROLOGY, 2013, 13
  • [12] COST-EFFECTIVENESS OF TELAPREVIR WITH PEGINTERFERON AND RIBAVIRIN FOR TREATMENT-NAIVE PATIENTS CHRONICALLY INFECTED WITH HCV OF GENOTYPE 1 IN JAPAN
    Ishida, H.
    Terai, S.
    Sakaida, I
    Inoue, Y.
    VALUE IN HEALTH, 2012, 15 (07) : A328 - A328
  • [13] Daclatasvir vs telaprevir in combination with peginterferon alfa/ribavirin in treatment-naive patients with HCV genotype 1: phase 3 COMMAND-3 results
    Jacobson, I.
    Zeuzem, S.
    Flisiak, R.
    Knysz, B.
    Lueth, S.
    Zarebska-Michaluk, D.
    Janczewska, E.
    Ferenci, P.
    Diago, M.
    Zignego, A.
    Safadi, R.
    Baruch, Y.
    Abdurakhmanov, D.
    Shafran, S.
    Thabut, D.
    Bruck, R.
    Gadano, A.
    Thompson, A.
    Kopit, J.
    McPhee, F.
    Michener, T.
    Hughes, E.
    Yin, P.
    Noviello, S.
    JOURNAL OF VIRAL HEPATITIS, 2014, 21 : 7 - 8
  • [14] THE COMPARATIVE EFFICACY OF TELAPREVIR VERSUS BOCEPREVIR IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS
    Diels, J.
    Cure, S.
    Gavart, S.
    VALUE IN HEALTH, 2011, 14 (07) : A266 - A266
  • [15] Optimal IFN-free therapy in treatment-naive patients with HCV genotype 1 infection
    Asselah, Tarik
    Marcellin, Patrick
    LIVER INTERNATIONAL, 2015, 35 : 56 - 64
  • [16] Health-related quality of life in genotype 1 treatment-naive chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study
    Vera-Llonch, M.
    Martin, M.
    Aggarwal, J.
    Donepudi, M.
    Bayliss, M.
    Goss, T.
    Younossi, Z.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 38 (02) : 124 - 133
  • [17] Predictors of Response to 24-Week Telaprevir-Based Triple Therapy for Treatment-Naive Genotype 1b Chronic Hepatitis C Patients
    Abe, Hiroshi
    Tsubota, Akihito
    Shimada, Noritomo
    Atsukawa, Masanori
    Kato, Keizo
    Takaguchi, Koichi
    Asano, Toru
    Chuganji, Yoshimichi
    Sakamoto, Choitsu
    Toyoda, Hidenori
    Kumada, Takashi
    Ide, Tatsuya
    Sata, Michio
    Aizawa, Yoshio
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2014, 2014
  • [18] EARLY VIROLOGICAL RESPONSE PROFILES WITH TELAPREVIR (T) IN COMBINATION WITH PEGINTERFERON-ALFA-2A (P) AND RIBAVIRIN (R) IN GENOTYPE 1 HCV TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS ARE SIMILAR
    Poordad, F.
    McHutchison, J. G.
    Shiffman, M. L.
    Berg, T.
    Muir, A. J.
    Manns, M. P.
    Di Bisceglie, A. M.
    Terrault, N.
    Picchio, G.
    Kwong, A.
    Bengtsson, L.
    George, S.
    Adda, N.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S121 - S122
  • [19] Triple therapy with boceprevir or telaprevir for treatment naive HCV patients
    Esteban, Rafael
    Buti, Maria
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2012, 26 (04) : 445 - 453
  • [20] ADVANCE study: Final results of the phase III trial with telaprevir in combination with PEG-IFN and RBV in treatment-naive genotype 1 HCV
    Rizzetto, M.
    Andreone, P.
    Colombo, M.
    Scuteri, A.
    Ciancio, A.
    Smedile, A.
    Adda, N.
    Jacobson, I. M.
    DIGESTIVE AND LIVER DISEASE, 2011, 43 : S69 - S69
12345